RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Just to note--the new management isn't that worried about the dronabinol license either--<<Regardless of whether such new license agreement is reached, due to its rights of inventorship and independent of the License Agreement, the Company remains free to practice additional patents and patent applications describing a dosage range for the use of dronabinol in the treatment of sleep apnea, as well as for various formulations of dronabinol>>.

But while the lack of interest in the UC license could mean a similar belief that they can work around IP that has a declining shelf life, it more likely means that they are focused on dronabinol and SA, not RD/Ampakines. Which, as we both would agree, is a shame.

How the three pools of RD/Ampakine IP and assets/compounds: UC, Cortex, Greer, now function as potential venues for continuing this work, I have no idea. If Cortex isn't going to use their compounds, they'd probably be happy to sell/license them. UC's license is no good to them unless a company licenses it, and as I said before, if someone was interested, Varney would probably have found them. I very much doubt that John Greer has access to anywhere near the level of funding necessary to continue Ampakine development, even if he could get access to compounds and regain all necessary IP.

The people with money have no interest, and the people with interest have no money. I keep thinking some midsize pain company is going to wake up and decide it's worth putting $20 million into this indication in the hope of developing a genuinely safer--as opposed to less-abusable--opioid painkiller.

But I've been thinking that for years, and I've tried to convince a few companies that this should be pursued, without success. I don't know what is going to change that.

NP